Gastroenterology: The therapeutic effect of bariatric surgery on obese non-alcoholic fatty hepatitis

Obesity is the primary risk factor for non-alcoholic fatty hepatitis (NASH), and bariatric surgery has a significant effect on improving symptoms in obese patients.
180 severely obese patients, and biopsy-confirmed NASH patients were involved in the study and underwent surgery at a weight loss centre in France for five years.
performed liver biopsies on 125 out of 169 patients a year later and 64 out of 94 five years later.
of the study was five years of liver biopsy NASH fibrosis without deterioration, the secondary endpoint was 5 years of fibrosis improvement of at least 1 level, fibrosis and NASH in 1 and 5 years receded.
5 years after bariatric surgery, NASH subsided and the proportion of patients with no deterioration of fibrosis was 84% (n-64).
70.2% of patients had lower fibrosis than the baseline.
56% of patients and 45.5% of baseline bridge fibrosis patients with fibrosis subsided.
persistent NASH symptoms were associated with no reduction in fibrosis and less weight (a 6.3 kg/m 2 reduction in BMI in patients with persistent NASH symptoms and a 13.4 reduction in BMI in patients with symptoms disappeared).
year after bariatric surgery, biopsies confirmed that 84% of patients had NASH receding and showed no signs of recurrence for 1-5 years.
1 year after surgery, fibrosis begins to decrease and continues to decline for 5 years.
study concluded that bariatric surgery had a sustained effect on obese non-alcoholic fatty hepatitis biopsy liver fiber and non-alcoholic fatty hepatitis symptoms, with 84% of patients seeing symptoms disappear 5 years after surgery and fibrosis decreasing 1-5 years after surgery.